214 related articles for article (PubMed ID: 26328451)
1. Preparation and Characterization of Chitosan Nanoparticles for Zidovudine Nasal Delivery.
Barbi Mda S; Carvalho FC; Kiill CP; Barud Hda S; Santagneli SH; Ribeiro SJ; Gremião MP
J Nanosci Nanotechnol; 2015 Jan; 15(1):865-74. PubMed ID: 26328451
[TBL] [Abstract][Full Text] [Related]
2. Mucoadhesive Nanostructured Polyelectrolyte Complexes as Potential Carrier to Improve Zidovudine Permeability.
Pedreiro LN; Stringhetti B; Cury F; Gremião MP
J Nanosci Nanotechnol; 2016 Feb; 16(2):1248-56. PubMed ID: 27433574
[TBL] [Abstract][Full Text] [Related]
3. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery.
Dalpiaz A; Fogagnolo M; Ferraro L; Beggiato S; Hanuskova M; Maretti E; Sacchetti F; Leo E; Pavan B
Eur J Pharm Biopharm; 2019 Nov; 144():91-100. PubMed ID: 31521715
[TBL] [Abstract][Full Text] [Related]
4. Nasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapy.
Carvalho FC; Campos ML; Peccinini RG; Gremião MP
Eur J Pharm Biopharm; 2013 May; 84(1):219-27. PubMed ID: 23207328
[TBL] [Abstract][Full Text] [Related]
5. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
6. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
7. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
8. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
9. Encapsulation of zidovudine in PF-68 coated alginate conjugate nanoparticles for anti-HIV drug delivery.
Joshy KS; Susan MA; Snigdha S; Nandakumar K; Laly AP; Sabu T
Int J Biol Macromol; 2018 Feb; 107(Pt A):929-937. PubMed ID: 28939525
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Stability and Mucoadhesive Properties of Chitosan Nanoparticles by Surface Modification with Sodium Alginate and Polyethylene Glycol for Potential Oral Mucosa Vaccine Delivery.
Amin MK; Boateng JS
Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323455
[No Abstract] [Full Text] [Related]
11. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine.
Hard SAAA; Shivakumar HN; Redhwan MAM
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127217. PubMed ID: 37793522
[TBL] [Abstract][Full Text] [Related]
12. Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting.
Belgamwar A; Khan S; Yeole P
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):374-386. PubMed ID: 28423949
[TBL] [Abstract][Full Text] [Related]
13. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
14. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the mucoadhesive properties of chitosan nanoparticles prepared using different chitosan to tripolyphosphate (CS:TPP) ratios.
Hejjaji EMA; Smith AM; Morris GA
Int J Biol Macromol; 2018 Dec; 120(Pt B):1610-1617. PubMed ID: 30282010
[TBL] [Abstract][Full Text] [Related]
16. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
17. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
18. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries.
Dalpiaz A; Fogagnolo M; Ferraro L; Capuzzo A; Pavan B; Rassu G; Salis A; Giunchedi P; Gavini E
Antiviral Res; 2015 Nov; 123():146-57. PubMed ID: 26427553
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
Raj R; Wairkar S; Sridhar V; Gaud R
Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729
[TBL] [Abstract][Full Text] [Related]
20. Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles.
Dalpiaz A; Ferraro L; Perrone D; Leo E; Iannuccelli V; Pavan B; Paganetto G; Beggiato S; Scalia S
Mol Pharm; 2014 May; 11(5):1550-61. PubMed ID: 24717116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
